Unique ID issued by UMIN | UMIN000002508 |
---|---|
Receipt number | R000003066 |
Scientific Title | Effect of combined therapy using balloon-ocluded arterial infusion of cisplatin with concurrent radiation for locally invasive bladder cancer: multi-center study |
Date of disclosure of the study information | 2009/09/17 |
Last modified on | 2009/09/16 13:56:49 |
Effect of combined therapy using balloon-ocluded arterial infusion of cisplatin with concurrent radiation for locally invasive bladder cancer: multi-center study
Effect of chemotherapy using cisplatin with concurrent radiation for locally invasive bladder cancer
Effect of combined therapy using balloon-ocluded arterial infusion of cisplatin with concurrent radiation for locally invasive bladder cancer: multi-center study
Effect of chemotherapy using cisplatin with concurrent radiation for locally invasive bladder cancer
Japan |
bladder cancer
Urology |
Malignancy
NO
We tested the usefulness of combined therapy using balloon-occluded arterial infusion of cisplatin with concurrent radiation in patient with locally advanced bladder cancer
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
progression free survival
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine | Maneuver |
BOAI-CDDP arterial infusion + radiation
Dose: CDDP 100mg x 1 + radiation 60Gy follow up duration: 5 years
Radical cystectomy with/without neoadjuvant or adjuvant chemotherapy
Not applicable |
Not applicable |
Male and Female
(1) patients who or whose family can agree with written informed consent
(2) patients with bladder cancer which is histologivally comfirmed urothelial cancer
(3) cTNM classification: T2-T3, N0, M0
(4) performance status: PS 0-2 (ECOG)
(5) patients who meet the following criteria
1. liver function; AST less than 2.5 times of the institutional upper limit of the normal range, total bilirubin less than; 2.0 times of the institutional upper limit of the normal range,
2. renal function; creatinin less than 1.5mg/dL,
3.cardiac function; tolerable function for the therapy,
4. bone-marrow; WBC more than 3,000/microL,
neutrophil more than 1,500/microL,
hemoglobin more than 10g/dL,
platelet more than 100,000/microL,
(6) regardless of age.
(1) Previous general treatment (radiation or chemotherapy) for the patients with bladder cancer.
(2) Patients who have severe complication (including serious diabetes) unable to be eligible for the study.
(3) Patients having another active cancer.
(4) Pregnant women, breast-feeding women, or women who will get pregnant.
(5) Others who are considered to be a ineligible for the study.
220
1st name | |
Middle name | |
Last name | Hideki Enokida |
Graduate School of Medical and Dental Sciences, Kagoshima University
Department of Urology
8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
099-275-5395
1st name | |
Middle name | |
Last name | Hideki Enokida |
Graduate School of Medical and Dental Sciences, Kagoshima University
Department of Urology
8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
099-275-5395
enokida@m.kufm.kagoshima-u.ac.jp
Department of urology, Osaka Medical College
none
Self funding
NO
鹿児島大学病院
2009 | Year | 09 | Month | 17 | Day |
Unpublished
Preinitiation
2009 | Year | 03 | Month | 23 | Day |
2009 | Year | 10 | Month | 01 | Day |
2019 | Year | 09 | Month | 01 | Day |
2019 | Year | 09 | Month | 01 | Day |
2019 | Year | 09 | Month | 01 | Day |
2020 | Year | 03 | Month | 01 | Day |
2009 | Year | 09 | Month | 16 | Day |
2009 | Year | 09 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003066